Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection-Reference-Cited by-同舟云学术

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

Published:2022-11-24 Issue:21 Volume:387 Page:1957-1968
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Yuen Man-Fung¹,Lim Seng-Gee¹,Plesniak Robert¹,Tsuji Keiji¹,Janssen Harry L.A.¹,Pojoga Cristina¹,Gadano Adrian¹,Popescu Corneliu P.¹,Stepanova Tatyana¹,Asselah Tarik¹,Diaconescu Gheorghe¹,Yim Hyung Joon¹,Heo Jeong¹,Janczewska Ewa¹,Wong Alexander¹,Idriz Nevin¹,Imamura Michio¹,Rizzardini Giuliano¹,Takaguchi Koichi¹,Andreone Pietro¹,Arbune Manuela¹,Hou Jinlin¹,Park Sung Jae¹,Vata Andrei¹,Cremer Jennifer¹,Elston Robert¹,Lukić Tamara¹,Quinn Geoff¹,Maynard Lauren¹,Kendrick Stuart¹,Plein Helene¹,Campbell Fiona¹,Paff Melanie¹,Theodore Dickens¹

Affiliation:

1. From the Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, and the State Key Laboratory of Liver Research, University of Hong Kong, Hong Kong (M.-F.Y.), and Nanfang Hospital, Southern Medical University, Guangzhou (J. Hou) — all in China; National University Health System, Singapore (S.-G.L.); the University of Rzeszow, College of Medical Sciences, Centrum Medyczne w Lancucie, Lancut (R.P.), and the Faculty of Health Sciences in Bytom, Medical...

Funder

GSK

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2210027

Reference26 articles.

1. Hepatitis B virus infection

2. New Approaches to the Treatment of Chronic Hepatitis B

3. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡